ASCENDO BIOTECHNOLOGY, INC. TAIWAN BRANCH (CAYMAN ISLANDS)
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
Their lead asset, ASD141, is a first‑in‑class monoclonal antibody that blocks the innate immune checkpoint TLT‑1 to reshape the tumor microenvironment and enhance anti‑tumor immunity.
They are also developing ASD001, an antibody aimed at rebalancing over
They are also developing ASD001, an antibody aimed at rebalancing over
Founded Year
2019
Unified Business No.
85070076
Status
Active
Number of Employees
12
Total Paid-in
Capital
0 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Ascendo Biotechnology, founded in 2019, is a clinical‑stage biotech company developing novel immunotherapies by targeting innate immune pathways to treat cancer and autoimmune diseases.
